The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York OncLive's FDA Approval Report: The Regulatory Rundown for March 2025 OncLive FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea The Unregulated World of Peptides: A Legal Minefield for Providers Holt Law Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences Frontiers Syzygium aromaticum (clove buds) as a natural antibacterial agent: a promising alternative to combat multidrug resistant bacteria